Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Discovery Grants Program - Individual

McMaster University

$66,000.00

Next-generation separation technologies for the advanced manufacturing of oncolytic viruses

FY 2023-24

Summary
Oncolytic viruses (OVs) are a special class of bio-therapeutic molecules being developed for the treatment of cancer. Given the recent approval of the first OV product (for advanced melanoma) by the US FDA, the excitement and expectations are at an all time high.  Currently over 40 clinical trials are being conducted worldwide and bio-therapeutic companies are making major investments in expanding and accelerating their pipeline of OV products. Canada is a major player in the OV field given our national network of world-class researchers (BioCanRx), who are discovering new OVs and novel ways to deliver OVs into cancer cells, and growing industry sector.  The commercial success of OV-based therapies is critically dependent on the development of large-scale OV manufacturing process that can achieve the activity and purity requirements established by regulatory agencies (e.g. Health Canada, FDA) while also being cost-effective. Given recent advances in 'upstream' OV manufacturing capacity, the accompanying 'downstream' separation processes are the major 'bottleneck' in OV manufacturing. The long-term vision of my research program is build the know-how, train the HQP, and develop the technologies to fix this problem.  In the short term, 4 PhD and 13 undergraduate students will carry out three interconnected projects to develop separation technologies that solve the critical 'technology gaps' that currently exist in large-scale OV manufacturing - they include: 1) Rational design of membrane chromatography processes for the production of OVs 2) Simultaneous purification, stabilization, and sterilization of OVs via diafiltration membrane process 3) Aptamer affinity chromatography process for the single-step purification of OVs The technologies will be developed for different OV candidates, however a significant focus will be on Maraba rhabdovirus given its potential use in the treatment of non-small cell lung cancer, the leading cause of cancer-related deaths in North America. Because bio-therapeutic manufacturers are reluctant to adopt new separation processes without extensive experimental validation, each project will include an assessment of process reproducibility and the development of theoretical frameworks. McMaster is the ideal venue to conduct this research given its world-class user facilities (Biointerfaces Institute, Centre for Microbial Chemical Biology) with state-of-the-art equipment. Most importantly, McMaster is also home to the Fitzhenry Manufacturing Facility (FMF), one of only two GMP suites in Canada with experience in producing pharmaceutical-grade OV products. While the FMF does not have the capacity to be used for commercial-scale production, it will allow for my team to demonstrate the 'proof-of-concept' at pilot-scale manufacturing. To my knowledge, there is no other group in Canada that has our expertise in separation processes plus this combination of infrastructure and equipment to execute a study of this kind.
Program
Discovery Grants Program - Individual
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
RGPIN-2019-06828
Name nom
Latulippe, David
Department département
Chemical Engineering
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2023
Competition year année de concours
2019
Award amount
66000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1511
Committee name en
Materials and Chemical Engineering
Committee name fr
Génie chimique et des matériaux
Area of application code
500
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Manufacturing processes and products
Area of application fr
Procédés et produits industriels
Research subject code
1806
Research subject group en
Chemical engineering
Research subject group fr
Separation processes
Research subject en
Génie chimique
Research subject fr
Procédés de séparation
Application title
Next-generation separation technologies for the advanced manufacturing of oncolytic viruses
Keyword
Aptamer affinity chromatography; Bioprocessing technology; Diafiltration; Downstream purification; High-throughput screening; Large-scale manufacturing; Microscale processing; Oncolytic viruses; Process scale-up; Sterile filtration
Application summary
Oncolytic viruses (OVs) are a special class of bio-therapeutic molecules being developed for the treatment of cancer. Given the recent approval of the first OV product (for advanced melanoma) by the US FDA, the excitement and expectations are at an all time high.  Currently over 40 clinical trials are being conducted worldwide and bio-therapeutic companies are making major investments in expanding and accelerating their pipeline of OV products. Canada is a major player in the OV field given our national network of world-class researchers (BioCanRx), who are discovering new OVs and novel ways to deliver OVs into cancer cells, and growing industry sector.  The commercial success of OV-based therapies is critically dependent on the development of large-scale OV manufacturing process that can achieve the activity and purity requirements established by regulatory agencies (e.g. Health Canada, FDA) while also being cost-effective. Given recent advances in 'upstream' OV manufacturing capacity, the accompanying 'downstream' separation processes are the major 'bottleneck' in OV manufacturing. The long-term vision of my research program is build the know-how, train the HQP, and develop the technologies to fix this problem.  In the short term, 4 PhD and 13 undergraduate students will carry out three interconnected projects to develop separation technologies that solve the critical 'technology gaps' that currently exist in large-scale OV manufacturing - they include: 1) Rational design of membrane chromatography processes for the production of OVs 2) Simultaneous purification, stabilization, and sterilization of OVs via diafiltration membrane process 3) Aptamer affinity chromatography process for the single-step purification of OVs The technologies will be developed for different OV candidates, however a significant focus will be on Maraba rhabdovirus given its potential use in the treatment of non-small cell lung cancer, the leading cause of cancer-related deaths in North America. Because bio-therapeutic manufacturers are reluctant to adopt new separation processes without extensive experimental validation, each project will include an assessment of process reproducibility and the development of theoretical frameworks. McMaster is the ideal venue to conduct this research given its world-class user facilities (Biointerfaces Institute, Centre for Microbial Chemical Biology) with state-of-the-art equipment. Most importantly, McMaster is also home to the Fitzhenry Manufacturing Facility (FMF), one of only two GMP suites in Canada with experience in producing pharmaceutical-grade OV products. While the FMF does not have the capacity to be used for commercial-scale production, it will allow for my team to demonstrate the 'proof-of-concept' at pilot-scale manufacturing. To my knowledge, there is no other group in Canada that has our expertise in separation processes plus this combination of infrastructure and equipment to execute a study of this kind.